Huyen Nguyen: Highlights from the NCCN Cancer-Associated Venous Thromboembolic Disease Guidelines
Huyen Nguyen, Clinical Pharmacist at Vinmec Healthcare System, shared on LinkedIn:
”NCCN Cancer-Associated Venous Thromboembolic Disease Guidelines Version 1.2026
Venous thromboembolism (VTE) remains one of the most common and potentially life-threatening complications in patients with cancer.
It is associated with increased morbidity, treatment interruptions, hospitalisations, and mortality.
Some important clinical updates and reminders:
- Cancer increases the risk of VTE several-fold compared with the general population, making risk assessment an essential component of routine oncology care.
- The Khorana Score remains one of the most validated tools for identifying ambulatory patients at high risk for chemotherapy-associated thrombosis.
- Direct oral anticoagulants (DOACs), including apixaban and rivaroxaban, are increasingly used for both thromboprophylaxis and treatment of cancer-associated thrombosis in appropriately selected patients.
- Extended thromboprophylaxis should be considered following major abdominal or pelvic cancer surgery in patients at high risk of postoperative VTE.
- Catheter-related thrombosis can often be managed with anticoagulation without immediate catheter removal when the device remains functional and clinically necessary.
Some practical clinical pearls:
- Assess thrombosis and bleeding risk before initiating anticoagulation
- Review renal function, hepatic function, platelet count, and drug interactions regularly
- Consider LMWH in selected patients with severe thrombocytopenia, gastrointestinal malignancies, genitourinary cancers, or concerns regarding DOAC absorption
- Evaluate interactions with targeted therapies, azole antifungals, anticonvulsants, and other CYP/P-gp modulators
- Reassess anticoagulation needs periodically as cancer status, treatment plans, and bleeding risks evolve
- Remember that active cancer often represents a persistent thrombotic risk factor, and anticoagulation beyond 3 months may be appropriate for selected patients
Another important reminder:
Optimal management of cancer-associated thrombosis requires multidisciplinary collaboration among oncologists, hematologists, pharmacists, surgeons, nurses, and thrombosis specialists to maximize efficacy while minimizing bleeding complications.”
Stay updated with Hemostasis Today.
-
Jun 7, 2026, 14:35Erica Wood: WHO Launches Landmark Action Framework to Secure Safe and Equitable Blood Supply Worldwide
-
Jun 7, 2026, 14:27Jorge Lima: Amniotic Fluid Embolism and Its Impact on Maternal and Perinatal Outcomes
-
Jun 7, 2026, 14:20Utsab Raj Panta: Navigating the A–E Classification in Acute Pulmonary Embolism
-
Jun 7, 2026, 14:19Ming Y Lim: The Burden and Impact of Bleeding in Newly Diagnosed Cancer Patients
-
Jun 7, 2026, 14:16What Would You Like to Know About Hemophilia Gene Therapy? – ISTH
-
Jun 7, 2026, 14:10Kamran Hajiyev: Reflections from The ICCA Stroke 2026
-
Jun 7, 2026, 14:08Faham Raza Jaffary: Beyond the Workplace – Driving Community Engagement and Empathy
-
Jun 7, 2026, 14:04Mayank Dwivedi: Transforming Outcomes Through Speed and Innovation In Stroke
-
Jun 7, 2026, 14:03Alejandro Gonzalez Veliz: What If Inflammation Is the Hidden Driver of Cardiovascular Disease?